50% off Premium Yearly
Prudential PLCPUKTOP PICKFeb 27, 2024Stock price when the opinion was issued
As of Jun 15, 2026. Market Open.
It is cheap at 10X earnings, with a 3.04% dividend. Momentum is good, with a 34% YTD gain. It has only lost money once in the past decade, and decent (10%+) growth is predicted. Prudential is on track to achieve its 10% (or higher) growth target for new-business profit (NBP), gross operating free surplus generation (OFSG), operating profit after tax (OPAT) and dividend per share. NBP gains will be driven by further strength at its flagship HK unit, led by active-agents expansion and a product-mix improvement toward health and protection policies. The latter will also be promoted across other key markets, along with the repricing of medical policies to bolster profitability. The mainland China unit could see a recovery in the new-business margin on strong sales of participating policies, despite the downturn in bond yields which lowered investment-return assumption. Robust new-business and cost-improvement effort will support OFSG and OPAT, the bases for dividend gains. We think it looks fine, but keep our first line above in mind, please.
Unlock Premium - Try 5i Free
Largest life insurer in the UK. Kind of a household name there. About half of its business is derived from Asia with the 2nd largest portion being from the US and a 3rd from the UK. This is a growth company, not a maximized dividend payout type, because the focus is on Asia. Good combination of defensiveness, cash generation and growth. The upside potential outweighs the downside risk.
Insurance company based in the UK. Have old legacy business, which is slow growing, as well as a business in the US plus a high growth business in Asia, which is insurance and wealth management. The Asian business is effectively the story. Strong balance sheet. 2.7% yield. There is a rumour that they may spin off the US asset which would create some big upside.
We reiterate PUK as a TOP PICK. Half year results showed new business profits up 39%, while raising the dividend by 9%. It trades at 11x earnings, under 2x book and generates a 20% ROE. Its dividend is backed by a modest 15% payout ratio. We continue to recommend a stop at $17, looking to achieve $29 -- upside potential over 35%. Yield 1.8%
(Analysts’ price target is $29.31)